Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
China has been tackling experimental COVID-19 vaccines to teams facing high infection risks since July, a health official told the state .
No vaccine has passed final, large-scale trials to show it is safe and effective enough to protect people from contracting the virus which has led to nearly 800,000 deaths worldwide.
The purpose is to enhance the immunity of particular groups of people, including medical employees and those who work in food markets and at the transportation and service sectors, Zheng Zhongwei, a National Health Commission official, told state TV in an interview aired late on August 22.
Authorities could contemplate expanding the emergency usage programme to attempt to stop potential outbreaks throughout the autumn and winter months, additional Zheng, who heads the Chinese government-led team that coordinates state resources such as COVID-19 vaccine growth.
The guidelines for emergency use of potential COVID-19 vaccines, approved on June 24 based on Zheng, have yet to be made public.
State press Global Times reported in June that China had been offering candidate COVID-19 offenses to employees at state-owned companies traveling overseas.
Some states are sceptical about China’s use of experimental vaccines. Papua New Guinea has denied entrance into Chinese nationals who participated in a COVID-19 vaccine trial, according to the Australian paper.
China’s COVID-19 vaccines will likely be priced close to cost, Zheng said.
“It does not necessarily mean that companies can’t generate gains,” Zheng said. “Companies should pick on moderate gains, or affordable profits based on prices.”
An expected COVID-19 vaccine being manufactured by a unit of China National Pharmaceutical Group (Sinopharm) could cost no more than 1,000 yuan ($144) for two shots, Sinopharm chairman Liu Jingzhen advised state media last week.
“[The price] will definitely be lower than that which Liu stated,” Zheng said.
